INT264861

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2008
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 4.25
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa2) protein folding (Apoa2) transport (Apoa2)
extracellular space (Apoa2) extracellular region (Apoa2)
Apoa2 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 19 58.52 Quite High
psoriasis 63 54.72 Quite High
Angina 5 52.04 Quite High
alcohol 3 44.12 Quite Low
Pain 3 35.60 Quite Low
Paresthesia 1 34.48 Quite Low
peripheral neuropathy 1 30.92 Quite Low
withdrawal 4 5.84 Low Low
Inflammation 20 5.00 Very Low Very Low Very Low
cytokine 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 90 100.00 Very High Very High Very High
Psoriasis 106 98.96 Very High Very High Very High
Nasopharynx Cancer 106 98.80 Very High Very High Very High
Cancer 37 95.56 Very High Very High Very High
Metastasis 6 95.12 Very High Very High Very High
Targeted Disruption 2 89.28 High High
Hyperlipidemia 5 88.12 High High
Congenital Anomalies 14 86.80 High High
Obesity 7 84.72 Quite High
Cardiovascular Disease 24 82.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
lipoprotein cholesterol (HDL-C) levels were measured by a
Regulation (cholesterol) of HDL associated with disorder of lipid metabolism
1) Confidence 0.44 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2656910 Disease Relevance 0.84 Pain Relevance 0.08
Percent change in HDL-C was 33.4% for dalcetrapib vs. 3.5% for placebo at Week 24, and 33.8 vs. 3.7% at Week 48 (each P < 0.0001 vs. placebo; TableĀ 2).
Regulation (change) of HDL associated with disorder of lipid metabolism
2) Confidence 0.26 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.51 Pain Relevance 0
Accordingly, the study sample size was based upon being able to evaluate changes in HDL-C over a 24-week period (due to its importance as an efficacy end point in establishing benefit to patients); thus, the sample size was planned on the basis of studies conducted to date.
Regulation (changes) of HDL associated with disorder of lipid metabolism
3) Confidence 0.26 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2821630 Disease Relevance 0.10 Pain Relevance 0
Many authors did not show any differences in apoA1, apoA2, and apoB levels between psoriatic patients and the control group [10, 76, 80].
Neg (not) Regulation (differences) of apoA2 associated with psoriasis
4) Confidence 0.21 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2914266 Disease Relevance 1.22 Pain Relevance 0.03
We also observed that suppression of the c-Myc signaling pathway was responsible for the ApoG2-induced cell cycle arrest.


Regulation (responsible) of ApoG2
5) Confidence 0.04 Published 2009 Journal J Transl Med Section Body Doc Link PMC2742515 Disease Relevance 1.12 Pain Relevance 0
In our study, the immunoblots data indicated that suppression of the c-Myc pathway might be responsible for ApoG2-induced cell cycle arrest in NPC cells.
Spec (might) Regulation (responsible) of ApoG2 associated with nasopharynx cancer
6) Confidence 0.04 Published 2009 Journal J Transl Med Section Body Doc Link PMC2742515 Disease Relevance 0.47 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox